Costanzo-Nordin M R
Department of Medicine, Loyola University of Chicago, Maywood, IL 60153.
J Heart Lung Transplant. 1992 May-Jun;11(3 Pt 2):S90-103.
This article reviews the literature and summarizes the data obtained at Loyola University of Chicago about the relationship between rejection, histocompatibility, and cardiac allograft vasculopathy. Both the studies concerning the relationship between rejection and cardiac allograft vasculopathy and those evaluating the impact of histocompatibility on cardiac allograft vasculopathy have produced conflicting results. Most studies are retrospective and include a small number of patients followed up for short periods of time and treated with variable immunosuppressive regimens. In addition, the diagnosis of cardiac allograft vasculopathy is based on angiographic detection of coronary arterial abnormalities, a method that is known to underestimate the presence and severity of cardiac allograft vasculopathy. The ability to assess the impact of histocompatibility on the development of cardiac allograft vasculopathy is also limited by the lack of uniformity in the type and number of HLA variables analyzed, the extreme polymorphism of the HLA antigens and variability in serologic tissue typing techniques and quality. The results of our study suggest that complete mismatch at the HLA-B and -DR loci is associated with higher rejection rates and severity and with increased mortality. We also noted a trend toward a higher incidence of cardiac allograft vasculopathy in patients with complete mismatch at the HLA-DR locus. Future experimental and clinical studies should be done with use of molecular tissue typing techniques to further elucidate the impact of histocompatibility on cardiac allograft vasculopathy. The role of non-HLA antigens in the development of cardiac allograft vasculopathy requires further definition. Because in heart transplantation the short donor ischemic times compatible with a successful outcome limit the feasibility of prospective donor/recipient tissue typing, the development of immunosuppressive drugs that effectively reduce the detrimental effects of tissue incompatibility is crucially needed.
本文回顾了相关文献,并总结了芝加哥洛约拉大学获得的关于排斥反应、组织相容性与心脏移植血管病变之间关系的数据。关于排斥反应与心脏移植血管病变关系的研究以及评估组织相容性对心脏移植血管病变影响的研究,均得出了相互矛盾的结果。大多数研究是回顾性的,纳入患者数量少,随访时间短,且采用了不同的免疫抑制方案。此外,心脏移植血管病变的诊断基于冠状动脉异常的血管造影检测,而这种方法已知会低估心脏移植血管病变的存在和严重程度。评估组织相容性对心脏移植血管病变发展影响的能力还受到以下因素限制:所分析的HLA变量的类型和数量缺乏一致性、HLA抗原的极端多态性以及血清学组织分型技术和质量的变异性。我们的研究结果表明,HLA - B和 - DR位点完全错配与更高的排斥反应发生率和严重程度以及更高的死亡率相关。我们还注意到,HLA - DR位点完全错配的患者中,心脏移植血管病变的发生率有升高趋势。未来应使用分子组织分型技术进行实验和临床研究,以进一步阐明组织相容性对心脏移植血管病变的影响。非HLA抗原在心脏移植血管病变发展中的作用需要进一步明确。由于在心脏移植中,与成功结果相容的短供体缺血时间限制了前瞻性供体/受体组织分型的可行性,因此迫切需要开发能有效降低组织不相容有害影响的免疫抑制药物。